The role of flumazenil in generalised anxiety disorder: a pilot naturalistic open-label study with a focus on treatment resistance.
Alexander T GalloStephen AddisVlad MartynHishani RamanathanGrace K WilkersonKellie S BennettSean D HoodHans StampferGary K HulsePublished in: Therapeutic advances in psychopharmacology (2023)
This study presents preliminary results for subcutaneous continuous low-dose FMZ's effectiveness and safety in GAD. The findings suggest that it is a safe, well-tolerated, and feasible treatment option in this group of patients. Future randomised control trials are needed in this field to determine the efficacy of this treatment.